Aytu BioPharma, Inc.
AYTUAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Ascendiant Capital | maintain | Buy | Sep 30, 2026 |
| Ascendiant Capital | maintain | Buy | Jun 11, 2026 |
| Ascendiant Capital | maintain | Buy | Dec 10, 2025 |
| Maxim Group | maintain | Buy | Sep 25, 2025 |
| Ascendiant Capital | maintain | Buy | Sep 25, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 31, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jul 21, 2022 |
| Cantor Fitzgerald | maintain | Overweight | May 17, 2022 |
| HC Wainwright & Co. | maintain | Buy | Apr 28, 2022 |
| Cantor Fitzgerald | maintain | Overweight | Mar 30, 2021 |
| HC Wainwright & Co. | maintain | Buy | Nov 25, 2020 |
| Northland Securities | maintain | Outperform | Nov 25, 2020 |
| HC Wainwright & Co. | maintain | Buy | May 29, 2020 |
| Northland Securities | maintain | Outperform | Oct 22, 2018 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.26| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Sep 22, 2026 | $-0.05 | $-0.29 | $16.1M | $12.3M |
| May 13, 2026 | $-0.53 | $-0.31 | $12.4M | $12.1M |
| Feb 3, 2026 | $-1.05 | $-0.26 | $15.2M | $12.2M |
| Nov 13, 2025 | $-0.08 | $-0.06 | $13.9M | $12.6M |
| Sep 23, 2025 | $-2.92 | $-0.02 | $15.1M | $17.9M |
| May 14, 2025 | $0.20 | $-0.17 | $18.5M | $13.7M |
| Feb 12, 2025 | $-0.28 | $-0.28 | $16.2M | $15.6M |
| Nov 13, 2024 | $-0.20 | $-0.34 | $16.6M | $13.8M |
News
ELTP and AYTU have different CNS portfolios, growth drivers and valuations, but which pharmaceutical stock looks better positioned? Let's dive in.
Aytu BioPharma, Inc. (AYTU) Q4 2026 Earnings Call Transcript
Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.26 per share a year ago.
Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter Fourth quarter fiscal 2026 Adjusted EBITDA of $0.5 million EXXUA net revenue of $6.6 million in fiscal 2026, including $3.9 million in the fourth quarter, following full commercial launch during third quarter fiscal 2026 EXXUA fourth quarter fiscal 2026 total prescriptions were 3,323, up approximately 138% from 1,398 in third quarter fiscal 2026 $26.3 million cash balance at June 3…
DENVER, CO / ACCESS Newswire / September 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2026 full year and fourth quarter, after the market close on Tuesday, September 22, 2026. The Company has scheduled a conference call and webcast that same day, Tues…
AWM Investment Company Inc. bought a new stake in Aytu BioPharma Inc. (NASDAQ: AYTU) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 619,574 shares of the company's stock, valued at approximately $1,332,000. AWM Investment Company Inc. owned